Idaho Medical Marijuana Ballot Initiative — Legalization Efforts and Timeline

Executive Summary

Idaho activists collected more than 150,000 signatures in May 2026 to place a medical marijuana initiative on the state ballot, marking the most significant effort yet to legalize cannabis in one of the nation's last prohibition strongholds. The signature drive, organized by the Idaho Medical Marijuana Coalition, exceeded the approximately 97,000 valid signatures required under Idaho law to qualify a constitutional amendment for the November 2026 ballot. If verified by the Idaho Secretary of State and approved by voters, the initiative would establish a regulated medical cannabis program for patients with qualifying conditions, ending Idaho's status as one of only three states with no legal cannabis access of any kind. The effort represents the culmination of decades of advocacy in a deeply conservative state where previous legalization attempts have failed, and where neighboring states' legal markets have created a complex cross-border dynamic that has shaped enforcement priorities and public opinion.

Why This Matters

Idaho's medical marijuana ballot initiative affects an estimated 20,000 to 30,000 Idaho residents who could qualify as medical cannabis patients, according to projections based on participation rates in neighboring states. The state's continued prohibition status has forced patients to choose between relocating, traveling to Oregon, Washington, Montana, or Nevada for legal access, or risking criminal prosecution under Idaho Code § 37-2732, which classifies marijuana possession as a misdemeanor punishable by up to one year in jail and a $1,000 fine for first-time offenders. The initiative carries significant implications for multiple stakeholder groups. Veterans comprise a substantial portion of potential patients, with Idaho hosting Mountain Home Air Force Base and a veteran population exceeding 120,000 according to U.S. Census data. Cancer patients, individuals with chronic pain, and those suffering from epilepsy have testified before the Idaho Legislature for years seeking legal access to medical cannabis. Parents of children with treatment-resistant epilepsy have become particularly vocal advocates, with several families publicly discussing their decisions to relocate to neighboring states to access CBD and cannabis-based treatments. From an economic perspective, the initiative would create Idaho's first legal cannabis market, potentially generating $50 million to $80 million in annual sales based on per-capita medical program performance in Montana and Utah. The measure includes provisions for state licensing of cultivation facilities, dispensaries, and testing laboratories, creating business opportunities in a state that has watched cannabis tax revenue flow to border communities in Oregon, Washington, and Nevada. Ontario, Oregon—directly across the Snake River from Idaho—has become a regional cannabis retail hub, with Idaho residents comprising an estimated 60% to 70% of customer traffic at dispensaries in Malheur County. Law enforcement resources currently dedicated to marijuana enforcement would be redirected under the initiative. Idaho State Police reported 3,847 marijuana-related arrests in 2024, with possession charges accounting for approximately 2,100 cases. The fiscal impact on county jails, court systems, and public defender offices has drawn attention from county commissioners in several Idaho counties facing budget constraints.

Background and History

Idaho has maintained complete cannabis prohibition since the federal Marihuana Tax Act of 1937, never wavering even as medical marijuana gained acceptance in 38 states and recreational use became legal in 24 states.

Early Prohibition Era (1937-1996)

Idaho adopted its first comprehensive marijuana prohibition statute in 1939, two years after federal prohibition began. The Idaho Uniform Narcotic Drug Act classified cannabis alongside opiates and cocaine, establishing criminal penalties that remained largely unchanged for decades. Throughout the 1960s and 1970s, as other states began decriminalizing small amounts of marijuana, Idaho maintained strict enforcement. The Idaho Legislature rejected decriminalization proposals in 1973, 1977, and 1981, with conservative lawmakers citing concerns about gateway drug theories and federal law supremacy.

The Medical Marijuana Movement Arrives (1996-2010)

California's passage of Proposition 215 in 1996 launched the modern medical marijuana era, but Idaho remained unmoved. The Idaho Legislature considered its first medical marijuana bill in 1999, introduced by then-Representative Wendy Jaquet. The measure died in committee without a hearing. Similar bills failed in 2001, 2003, 2005, 2007, and 2009, never receiving floor votes in either chamber. The Idaho Sheriffs' Association and Idaho Prosecuting Attorneys Council consistently opposed medical marijuana legislation throughout this period, arguing that federal prohibition under the Controlled Substances Act preempted state legalization efforts. Idaho Attorney General Lawrence Wasden issued a formal opinion in 2004 stating that state employees could face federal prosecution if Idaho established a medical marijuana program, a position that influenced legislative debates for years.

First Ballot Initiative Attempt (2012-2013)

Frustrated by legislative inaction, activists formed the Idaho Cannabis Coalition in 2012 to pursue a ballot initiative. Idaho's initiative process requires collecting signatures equal to 6% of registered voters in 18 of Idaho's 35 legislative districts, a geographic distribution requirement that makes qualification significantly more difficult than in states requiring only a statewide signature threshold. The 2012-2013 effort collected approximately 47,000 signatures but failed to meet the 18-district requirement, falling short in rural eastern Idaho counties.

CBD Oil Exception (2015)

The Idaho Legislature passed Senate Bill 1146 in 2015, creating a narrow exception for CBD oil containing less than 0.3% THC for patients with intractable epilepsy. The law, codified as Idaho Code § 37-2732A, required patients to obtain CBD through FDA-approved sources and established an affirmative defense to prosecution rather than full legalization. The measure passed only after parents of children with epilepsy testified emotionally before legislative committees, and even then passed the House by just 38-32. The CBD exception remains Idaho's only legal cannabis access pathway, though its restrictive requirements have limited its practical use to fewer than 200 patients statewide.

Regional Legalization Pressure (2016-2020)

As neighboring states legalized marijuana, Idaho faced increasing pressure. Oregon legalized recreational marijuana in 2015, Washington in 2012, Montana medical marijuana in 2004 (and recreational in 2020), and Nevada recreational in 2017. By 2020, Idaho was surrounded by legal cannabis markets, creating enforcement challenges for Idaho State Police at border crossings. The Idaho Legislature responded by strengthening prohibition. House Bill 1 in 2019 proposed a constitutional amendment to permanently ban marijuana legalization, requiring a two-thirds legislative vote to ever change course. The measure passed the House 57-13 but died in the Senate after concerns were raised about limiting future legislative flexibility.

Second Initiative Attempt (2020-2021)

The Idaho Medical Marijuana Coalition formed in 2019 and launched a signature drive in 2020 for the 2022 ballot. The campaign collected approximately 75,000 signatures but was derailed by COVID-19 restrictions on in-person signature gathering and legal challenges to signature verification procedures. The Idaho Secretary of State's office invalidated thousands of signatures due to technical deficiencies, and the initiative failed to qualify.

Third Attempt and Current Campaign (2024-2026)

Learning from previous failures, organizers restructured their approach for the 2024-2026 cycle. The Idaho Medical Marijuana Coalition hired professional signature-gathering firms, established paid canvasser teams in all 18 required legislative districts, and raised approximately $2.3 million according to campaign finance disclosures filed with the Idaho Secretary of State. The campaign launched signature gathering in June 2024 after the initiative text received approval from the Attorney General's office. The initiative text proposes amending the Idaho Constitution to establish a medical marijuana program for patients with debilitating medical conditions including cancer, glaucoma, HIV/AIDS, hepatitis C, ALS, Crohn's disease, Alzheimer's disease, PTSD, chronic pain, and severe nausea. The measure would require the Idaho Department of Health and Welfare to establish a registry identification card system and license cultivation facilities, dispensaries, and testing laboratories. Patients could possess up to four ounces of usable marijuana and grow up to six plants for personal medical use. The May 2026 announcement that signature gatherers collected more than 150,000 signatures—approximately 55% above the required threshold—represented a breakthrough moment. The Idaho Secretary of State has 60 days to verify signatures, checking each against voter registration records and applying the 18-district geographic distribution test. Campaign organizers expressed confidence that the cushion would withstand the verification process, with invalid signatures typically ranging from 20% to 30% of total submissions in Idaho initiative campaigns.

Key Players

Idaho Medical Marijuana Coalition

The Idaho Medical Marijuana Coalition serves as the primary campaign organization behind the 2026 ballot initiative. The group formed in 2019 and is led by campaign director Russ Belville, a cannabis policy advocate who previously worked on Oregon legalization campaigns. The coalition built a grassroots network of volunteers across Idaho's 44 counties, with particularly strong organization in Ada County (Boise), Kootenai County (Coeur d'Alene), and Bonneville County (Idaho Falls). The organization raised funds through small-dollar donations, out-of-state contributions from national marijuana policy reform organizations, and in-state donors including medical professionals and business leaders.

Idaho Legislature

The Idaho Legislature has consistently opposed marijuana legalization, with Republican supermajorities in both chambers maintaining prohibition policies. Senate Majority Leader Chuck Winder and House Speaker Mike Moyle have both stated opposition to medical marijuana legalization, citing federal law conflicts and concerns about recreational use normalization. However, the legislature's role becomes limited once an initiative qualifies for the ballot, as Idaho's constitutional amendment process bypasses legislative approval.

Idaho Governor Brad Little

Governor Brad Little has not taken a formal position on the 2026 ballot initiative as of May 2026, but previously stated opposition to marijuana legalization during his 2018 and 2022 gubernatorial campaigns. Little emphasized law enforcement concerns and federal prohibition in past statements. The governor's position carries weight with conservative voters but does not directly affect ballot qualification.

Idaho Sheriffs' Association

The Idaho Sheriffs' Association has opposed previous marijuana legalization efforts and is expected to campaign against the 2026 initiative. The organization represents Idaho's 44 elected county sheriffs and has argued that marijuana legalization increases impaired driving, complicates law enforcement, and conflicts with federal law. Canyon County Sheriff Kieran Donahue has been particularly vocal, citing experiences in neighboring Oregon as cautionary examples.

Idaho Medical Association

The Idaho Medical Association has not taken an official position on the 2026 initiative as of May 2026. The organization represents approximately 2,800 physicians across Idaho. Individual physicians have testified both for and against medical marijuana in legislative hearings, with supporters citing patient testimonials and research on cannabis efficacy for chronic pain and seizure disorders, while opponents have raised concerns about lack of FDA approval and dosing standardization.

Veterans Organizations

Several Idaho veterans groups have endorsed medical marijuana access, including local chapters of Veterans of Foreign Wars and the American Legion. Idaho veteran advocate John Miller, a retired Army sergeant who served in Iraq, has been a prominent campaign spokesperson, discussing his use of cannabis for PTSD symptoms and the challenges of accessing treatment in a prohibition state.

Opposition Groups

Smart Approaches to Marijuana (SAM), a national anti-legalization organization, has indicated plans to establish an Idaho chapter to oppose the ballot initiative. The group argues that medical marijuana programs serve as pathways to recreational legalization and that FDA-approved cannabis-derived medications like Epidiolex provide safer alternatives. Idaho Family Policy Center, a conservative advocacy organization, has also expressed opposition based on concerns about youth access and social costs.

Legal and Regulatory Framework

Idaho's current marijuana prohibition rests on Idaho Code § 37-2732, which classifies marijuana as a Schedule I controlled substance under state law, mirroring federal classification under 21 U.S.C. § 812. Idaho Code § 37-2732(c) makes it unlawful to possess marijuana, with first-time possession of three ounces or less classified as a misdemeanor punishable by up to one year in county jail and a fine up to $1,000. Possession of more than three ounces becomes a felony under Idaho Code § 37-2732(a)(1)(A), punishable by up to five years in prison. Cultivation, delivery, and trafficking carry enhanced penalties, with trafficking in marijuana (defined as possession of one pound or more) carrying mandatory minimum sentences under Idaho Code § 37-2732B. The proposed constitutional amendment would supersede these statutes by establishing medical marijuana as a constitutional right for qualifying patients. Idaho's constitution can be amended through the initiative process outlined in Article III, Section 1 of the Idaho Constitution, which requires signatures from 6% of qualified electors in each of 18 legislative districts. Once an initiative qualifies for the ballot, it requires a simple majority of votes cast to be adopted. Constitutional amendments take effect 30 days after the election unless otherwise specified in the amendment text. The initiative text specifies that the Idaho Department of Health and Welfare would promulgate administrative rules within 180 days of passage to establish the medical marijuana program. These rules would address registry identification card applications, qualifying physician certification requirements, dispensary licensing standards, cultivation facility regulations, testing laboratory protocols, and possession limits. The measure includes language preempting local governments from prohibiting medical marijuana facilities, though it allows reasonable time, place, and manner restrictions through zoning ordinances. Federal law complications remain significant. The Controlled Substances Act classifies marijuana as a Schedule I substance under 21 U.S.C. § 812, making cultivation, distribution, and possession federal crimes. However, the Rohrabacher-Farr Amendment (now the Joyce-Leahy Amendment), renewed annually in congressional appropriations bills, prohibits the Department of Justice from using federal funds to prevent states from implementing medical marijuana laws. This provision has provided practical protection for state-legal medical marijuana programs since 2014, though it does not create a permanent safe harbor. Banking access remains restricted under federal law. The Bank Secrecy Act and federal anti-money laundering statutes make financial institutions reluctant to serve cannabis businesses, forcing many dispensaries to operate on a cash basis. The SAFE Banking Act, which would provide explicit protections for financial institutions serving state-legal cannabis businesses, has passed the U.S. House multiple times but has not become law as of May 2026. Tax treatment under Internal Revenue Code § 280E prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses, creating effective tax rates of 70% or higher for cannabis businesses. Idaho medical marijuana dispensaries would face this federal tax burden even if operating legally under state law.

State-by-State Context

Idaho is one of only three states with no legal cannabis access as of May 2026, alongside Nebraska and Kansas, making the ballot initiative particularly significant in the national legalization landscape.

Neighboring States

Oregon

Oregon legalized medical marijuana in 1998 and recreational marijuana in 2015. The state operates a mature cannabis market with more than 600 licensed dispensaries. Oregon's proximity has created a significant cross-border market, with Idaho residents traveling to Ontario, Huntington, and other border communities for legal purchases. Oregon dispensaries cannot legally sell to out-of-state residents under Oregon Administrative Rules 845-025-1015, but enforcement of residency requirements has been inconsistent. Idaho State Police maintain checkpoints on Interstate 84 and U.S. Highway 95 near the Oregon border, conducting searches for marijuana being transported into Idaho.

Washington

Washington legalized recreational marijuana in 2012 through Initiative 502. The state's northern border with Idaho has created similar dynamics to the Oregon border, with Spokane-area dispensaries drawing Idaho customers. Washington allows possession of up to one ounce for adults 21 and older and operates approximately 500 licensed retail stores statewide.

Montana

Montana legalized medical marijuana in 2004 and recreational marijuana in 2020 through Initiative 190. The program allows medical patients to possess up to one ounce and grow up to four mature plants. Montana's eastern border with Idaho has seen less cross-border traffic than Oregon and Washington borders due to longer distances to major Idaho population centers, but dispensaries in Missoula serve some Idaho customers.

Nevada

Nevada legalized medical marijuana in 2000 and recreational marijuana in 2017. Nevada allows adults 21 and older to possess up to one ounce and operate a robust commercial market in Las Vegas and Reno. Nevada's southern border with Idaho is sparsely populated, limiting cross-border dynamics compared to Oregon and Washington.

Utah

Utah legalized medical marijuana in 2018 through Proposition 2, later modified by the Utah Legislature. Utah's program is among the most restrictive in the nation, prohibiting smokable flower and limiting access to capsules, topicals, and other forms. Utah allows possession of up to 113 grams (approximately four ounces) in a 30-day period for registered patients. Utah's conservative political culture and restrictive program design have been cited by Idaho advocates as a model for building support among skeptical voters.

Wyoming

Wyoming maintains complete marijuana prohibition similar to Idaho, with no medical or recreational program. Wyoming's shared border with Idaho has not created the same cross-border market dynamics as states with legal cannabis.

National Landscape

As of May 2026, 38 states have legalized medical marijuana and 24 states have legalized recreational marijuana. The national trend toward legalization has accelerated since 2012, with conservative states including Oklahoma, Arkansas, and Mississippi establishing medical programs. Idaho's continued prohibition status has become increasingly anomalous, particularly given its geographic position surrounded by legal states.

Market and Business Implications

Idaho's medical marijuana market could generate $50 million to $80 million in annual sales based on population-adjusted comparisons to Montana and Utah medical programs. Idaho's population of approximately 1.95 million would support an estimated 20,000 to 30,000 registered medical marijuana patients based on participation rates of 1% to 1.5% observed in restrictive medical-only states. At average annual spending of $2,500 to $3,000 per patient, total market size would reach the $50 million to $80 million range within three years of program implementation. The initiative text does not specify the number of cultivation or dispensary licenses the state would issue, leaving that determination to administrative rulemaking by the Idaho Department of Health and Welfare. Industry analysts expect Idaho would likely adopt a limited-license model similar to Utah or Montana rather than an open-market approach like Oregon. Limited licensing would create significant value for initial license holders but could restrict patient access in rural areas. Multi-state operators (MSOs) including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs have expressed interest in Idaho market entry if the initiative passes, according to industry publications. However, Idaho's relatively small population and medical-only program structure make it less attractive than larger markets or recreational states. Regional operators based in neighboring states appear more likely to dominate initial market development. Real estate implications include demand for cultivation facilities, processing facilities, dispensary locations, and testing laboratories. Cultivation facilities typically require 10,000 to 50,000 square feet of industrial space with significant electrical capacity for indoor growing operations. Dispensaries require retail-zoned locations with parking and security features. Idaho's commercial real estate market in Boise, Coeur d'Alene, Idaho Falls, Pocatello, and Twin Falls would see immediate demand if the initiative passes. Employment impacts include direct jobs in cultivation, processing, retail, testing, and security, plus indirect jobs in legal services, accounting, marketing, and ancillary businesses. Montana's medical marijuana program employs approximately 1,500 people directly in a state with a population of 1.1 million, suggesting Idaho could support 2,500 to 3,000 direct cannabis industry jobs. Tax revenue projections depend on the tax structure established in implementing legislation. The initiative text does not specify tax rates, leaving that to the Idaho Legislature. If Idaho adopted a 10% excise tax on medical marijuana sales (comparable to Montana's rate), annual tax revenue could reach $5 million to $8 million at market maturity. However, Idaho Code § 63-3638 currently prohibits state sales tax on prescription drugs, and legal questions exist about whether medical marijuana would be classified as a prescription drug or a separate category for tax purposes. Banking and financial services challenges would affect Idaho cannabis businesses due to federal prohibition and Internal Revenue Code § 280E. Idaho-based credit unions and community banks have indicated reluctance to serve cannabis clients without federal safe harbor protections. This would likely force Idaho dispensaries to operate largely in cash, creating security risks and operational inefficiencies. Capital formation for Idaho cannabis businesses would face restrictions due to federal prohibition. Traditional bank loans and Small Business Administration financing remain unavailable to cannabis businesses. Equity financing from venture capital and private equity firms has become more common in the cannabis industry, but valuations in medical-only markets are typically lower than recreational markets. Idaho entrepreneurs would likely need to raise capital from specialized cannabis investment funds or high-net-worth individuals with cannabis industry experience.

What Experts Say

Medical marijuana policy experts describe Idaho's ballot initiative as a critical test of whether conservative states will continue moving toward cannabis acceptance or whether prohibition can hold in the face of regional legalization pressure. Paul Armentano, deputy director of the National Organization for the Reform of Marijuana Laws (NORML), said the Idaho campaign represents one of the most challenging legalization efforts in the country due to the state's conservative political culture and strong law enforcement opposition. Armentano noted that successful medical marijuana campaigns in conservative states have typically emphasized patient stories, veteran support, and restrictive program designs that limit recreational use concerns. Dr. Kevin Sabet, president of Smart Approaches to Marijuana, has argued that medical marijuana initiatives often serve as stepping stones to recreational legalization and that FDA-approved cannabis-derived medications provide safer alternatives for patients. Sabet has pointed to increased youth marijuana use in some legalization states as evidence of social costs. Mason Tvert, a cannabis policy consultant who led Colorado's successful legalization campaigns, said Idaho's geographic isolation as a prohibition state surrounded by legal markets creates unique political dynamics. According to Tvert, cross-border enforcement issues and lost tax revenue to neighboring states can shift public opinion even in conservative areas. Dr. Sunil Aggarwal, a Seattle-based palliative care physician and medical cannabis researcher, has described the therapeutic potential of cannabis for chronic pain, nausea, and other conditions. Aggarwal noted that many patients report better outcomes with whole-plant cannabis compared to isolated cannabinoids like FDA-approved Epidiolex, though he acknowledged the need for more rigorous clinical research. Beau Kilmer, director of the RAND Drug Policy Research Center, said medical marijuana program design significantly affects outcomes including patient access, diversion to non-medical use, and public health impacts. According to Kilmer, restrictive programs like Utah's minimize diversion risks but may limit patient access, while permissive programs like California's pre-2016 medical system created widespread recreational use under medical pretenses.

What's Next

The Idaho Secretary of State has until mid-July 2026 to verify the 150,000-plus signatures submitted by the Idaho Medical Marijuana Coalition, with ballot qualification requiring approximately 97,000 valid signatures distributed across at least 18 of Idaho's 35 legislative districts. The verification process involves checking each signature against voter registration records, confirming signers are registered Idaho voters, and validating that signatures were collected within the 18-month window allowed under Idaho law. Historical data from previous Idaho initiative campaigns suggests invalidation rates of 20% to 30% due to duplicate signatures, non-registered signers, and technical deficiencies. Campaign organizers built a 55% cushion above the minimum requirement specifically to withstand expected invalidations. If the initiative qualifies, it will appear on the November 2026 general election ballot. Campaign activity would intensify through the summer and fall, with both supporters and opponents raising funds for advertising, grassroots organizing, and voter outreach. Television advertising in the Boise media market, which reaches approximately 60% of Idaho voters, typically costs $500,000 to $1 million for a sustained campaign. Radio, digital advertising, direct mail, and field operations would require additional resources. Polling data on Idaho voter attitudes toward medical marijuana has been limited, with no major public polls conducted since 2023. A Boise State University public policy survey in 2023 found 52% of Idaho voters supported medical marijuana legalization, with 38% opposed and 10% undecided. Support was strongest among voters under 50, independents, and residents of Ada County (Boise). Opposition was strongest among voters over 65, Republicans, and residents of rural eastern Idaho counties. Legal challenges to the initiative could emerge before or after the election. Opponents could challenge the signature verification process, the initiative's compliance with Idaho's single-subject rule for ballot measures, or the constitutionality of specific provisions. Idaho's single-subject rule, established in Idaho Constitution Article III, Section 16, requires that initiatives address only one subject to prevent logrolling. Medical marijuana initiatives have survived single-subject challenges in other states by arguing that all provisions relate to the single subject of medical marijuana access. If voters approve the initiative in November 2026, implementation would begin 30 days after the election. The Idaho Department of Health and Welfare would have 180 days to promulgate administrative rules establishing the medical marijuana program. This timeline suggests patient registry applications could begin in mid-2027, with dispensaries opening in late 2027 or early 2028 depending on licensing timelines. The Idaho Legislature could attempt to amend or repeal the initiative after passage, but constitutional amendments require a two-thirds vote in both chambers to modify. Given Republican supermajorities in the Idaho Legislature, such action is theoretically possible but would face significant political backlash if voters approved the initiative by a substantial margin. Federal policy changes could affect implementation. If Congress passes the SAFE Banking Act or deschedules marijuana under the Controlled Substances Act, banking access and tax treatment would improve significantly for Idaho cannabis businesses. Conversely, a change in federal enforcement priorities could create uncertainty for state programs, though such a shift appears unlikely given bipartisan congressional support for state medical marijuana programs.

Further Reading

• Idaho Code § 37-2732 (marijuana prohibition statute) - https://legislature.idaho.gov/statutesrules/idstat/Title37/T37CH27/SECT37-2732/
• Idaho Constitution Article III, Section 1 (initiative and referendum process) - https://legislature.idaho.gov/statutesrules/idconst/ArtIII/Sect1/
• Idaho Secretary of State Elections Division (initiative tracking and verification) - https://sos.idaho.gov/elections-division/
• 21 U.S.C. § 812 (federal Controlled Substances Act scheduling) - https://www.law.cornell.edu/uscode/text/21/812
• Internal Revenue Code § 280E (cannabis business tax restrictions) - https://www.law.cornell.edu/uscode/text/26/280E
• Idaho Department of Health and Welfare (future regulatory authority) - https://healthandwelfare.idaho.gov/
• RAND Drug Policy Research Center cannabis policy research - https://www.rand.org/topics/cannabis-policy.html
• National Conference of State Legislatures medical marijuana state laws database - https://www.ncsl.org/health/state-medical-cannabis-laws
• Idaho State Police drug enforcement statistics - https://isp.idaho.gov/
• Montana Department of Revenue cannabis tax data (comparable market) - https://mtrevenue.gov/cannabis/